Hesai Group - American Depositary Share (HSAI)
Live price chart, market sentiment, and community perspectives for Hesai Group - American Depositary Share (NASDAQ: HSAI).
Live price chart, market sentiment, and community perspectives for Hesai Group - American Depositary Share (NASDAQ: HSAI).
On our desk, the valuation picture is a bit complex. With a trailing P/E of 37.6x and a P/S ratio sitting around 6.29x—slightly above its historical median of 6.14x—the market is actively pricing in sustained multi-year growth. However, because the company recently printed a non-recurring one-off gain of CNY 190.7m within its earnings, we have to look past the headline numbers to gauge true organic operating cash flow before scaling up our long exposure.
Watching the macro regulatory headlines, the single biggest tail risk for HSAI remains potential U.S. legislation targeting Chinese LiDAR hardware and a possible BIS Entity List designation. While I personally assign only a 10% to 15% probability to an Entity List designation over a 12-month horizon, that localized policy overhang is precisely why the stock trades at a roughly 27% discount to its peer group median of 5.5x NTM revenue.
From a fundamental reporting perspective, the operational metrics are undeniably strong. Shifting over 628,000 lidar units in Q2 alone and guiding for Q3 revenue between RMB 1,100 million and RMB 1,150 million demonstrates massive enterprise velocity. Crossing five consecutive quarters of GAAP profitability marks a major milestone for a pure-play hardware maker, giving management clear credibility on cost control.
As a hedge fund portfolio manager tracking Asian tech, I am maintaining a HOLD rating for now. Even though the company boasts a 33% global market share and partnerships with major brands like Toyota and NVIDIA, intensifying domestic and international competition—especially from Huawei—creates severe margin pressures that could compress multiples if top-line growth decelerates.
Running our quant models on the recent equity price action, the stock rallied past $17.47 following the Q2 print, buoyed by net income rising 60% year-on-year to RMB 70.6 million. Yet, with a GF Score of 55/100 reflecting strong financial strength offset by weaker profitability metrics and valuation headwinds, we are waiting for a cleaner entry point before deploying fresh capital.
Explore plasma cleansing, somatic organ swaps, and BCI.